Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $8.4 million.

  • Ironwood Pharmaceuticals' Interest Expenses fell 1045.76% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 378.27%. This contributed to the annual value of $33.0 million for FY2024, which is 5273.01% up from last year.
  • Ironwood Pharmaceuticals' Interest Expenses amounted to $8.4 million in Q3 2025, which was down 1045.76% from $8.4 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Interest Expenses' 5-year high stood at $9.8 million during Q3 2023, with a 5-year trough of $1.5 million in Q3 2022.
  • Its 5-year average for Interest Expenses is $6.2 million, with a median of $7.7 million in 2021.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Interest Expenses tumbled by 8080.74% in 2022 and then soared by 54560.37% in 2023.
  • Ironwood Pharmaceuticals' Interest Expenses (Quarter) stood at $8.0 million in 2021, then plummeted by 80.81% to $1.5 million in 2022, then surged by 451.97% to $8.4 million in 2023, then increased by 5.83% to $8.9 million in 2024, then fell by 5.38% to $8.4 million in 2025.
  • Its Interest Expenses was $8.4 million in Q3 2025, compared to $8.4 million in Q2 2025 and $8.1 million in Q1 2025.